Choroidal Neovascularization - Pipeline Review, H1 2018

  • ID: 4482722
  • Drug Pipelines
  • 47 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Formycon AG
  • Iconic Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Lupin Ltd
  • Mabion SA
  • MORE
Choroidal Neovascularization - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Choroidal Neovascularization - Pipeline Review, H1 2018, provides an overview of the Choroidal Neovascularization (Ophthalmology) pipeline landscape.

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes ant-VEGF agents, laser photocoagulation and photodynamic therapy.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Choroidal Neovascularization - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Choroidal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Choroidal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization (Ophthalmology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Choroidal Neovascularization (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Choroidal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Formycon AG
  • Iconic Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Lupin Ltd
  • Mabion SA
  • MORE
Introduction

Report Coverage

Choroidal Neovascularization - Overview

Choroidal Neovascularization - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Choroidal Neovascularization - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Choroidal Neovascularization - Companies Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd

Formycon AG

Iconic Therapeutics Inc

Isarna Therapeutics GmbH

Lupin Ltd

Mabion SA

NovelMed Therapeutics Inc

Noxxon Pharma AG

Promedior Inc

Choroidal Neovascularization - Drug Profiles

ACX-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ayuv-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Calreticulin for Choroidal Neovascularization - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICON-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-0036 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-9405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRM-167 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Choroidal Neovascularization - Dormant Projects

Choroidal Neovascularization - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Choroidal Neovascularization, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Choroidal Neovascularization - Pipeline by Formycon AG, H1 2018

Choroidal Neovascularization - Pipeline by Iconic Therapeutics Inc, H1 2018

Choroidal Neovascularization - Pipeline by Isarna Therapeutics GmbH, H1 2018

Choroidal Neovascularization - Pipeline by Lupin Ltd, H1 2018

Choroidal Neovascularization - Pipeline by Mabion SA, H1 2018

Choroidal Neovascularization - Pipeline by NovelMed Therapeutics Inc, H1 2018

Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H1 2018

Choroidal Neovascularization - Pipeline by Promedior Inc, H1 2018

Choroidal Neovascularization - Dormant Projects, H1 2018

Choroidal Neovascularization - Dormant Projects, H1 2018 (Contd..1), H1 2018

Choroidal Neovascularization - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Choroidal Neovascularization, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • F. Hoffmann-La Roche Ltd
  • Formycon AG
  • Iconic Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Lupin Ltd
  • Mabion SA
  • NovelMed Therapeutics Inc
  • Noxxon Pharma AG
  • Promedior Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll